systematic-review-of-population-pharmacokinetic-models-of-isoniazid-in-children-and-adults-with-tuberculosis

Introduction: Isoniazid (INH) is one of the first-line anti-tuberculosis (anti-TB) drugs that have both bactericidal and bacteriostatic properties depending on rate mycobacterial growth. Several population pharmacokinetic (PPK) models INH were established. This systemic review aims to summarise published PPK parameters in identify covariates influencing models. Method: A search publications for analyses volunteers or TB patients from 2011 2021 was conducted PubMed Scopus databases. Reviews, methodology articles, non-compartmental analysis, vitro, animal studies excluded. Result: Twelve included this review. Most described pharmacokinetics as two-compartmental with first-order absorption elimination most studies. Eleven reported N-acetyltransferase 2 (NAT2) genotype polymorphism common significant covariate affecting INH. Other include body weight (n = 2) mass index (BMI) 1). Conclusion: The variability clearance explained mainly by NAT2 polymorphism. indicates optimise rationalise dosing regimen INH, a patient’s should be considered. At same time, BMI values considered when making adjustments achieve therapeutic range.